Niki BioSolutions, Inc.
NIKIHealthcare|Biotechnology|US
$1.58
+0.08 (+5.33%)
DCF Value
$0.14
Tangible Book / Share
$187.59
Cash / Share
$46.97
About
Niki BioSolutions is a biopharmaceutical company that resulted from the merger of Aptorum Group and DiamiR Biosciences. The company focuses on developing and commercializing a diverse portfolio of therapeutic and diagnostic assets. Its work spans from treatments for diseases with unmet medical needs, particularly in oncology and infectious diseases, to the development of innovative, blood-based diagnostic tests for brain health and other conditions.
Stock Price
-98.8%(1Y)
1M
-63.4%
3M
-82.4%
6M
-98.1%
YTD
-98.5%
1Y
-98.9%
3Y
-98.9%
5Y
-99.9%
Pipeline Summary
0 total trials0
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
Key Facts
Market Cap$128.7K
Employees1
CEOChung Yuen Huen
IPO DateJul 20, 2026
Beta0.17
52-Week Range$1.415 – $17.2
Avg Volume119,210
ExchangeNASDAQ
Websiteaptorumgroup.com
Ownership
Float65.8%
Shares Outstanding0.1M
Recent Insider Trades
Philips Laura AAWARD
Jul 22, 20268,000 shares @ $8.83
Sheinerman KiraAWARD
Jul 22, 20268,000 shares @ $8.83
Sheinerman KiraAWARD
Jul 22, 20268,000 shares @ $8.83
Arner Douglas WayneOTHER
Jul 20, 20260 shares
Wu Justin Che YuenOTHER
Jul 20, 20260 shares
Recent News
Niki BioSolutions Announces New York State Approval for Its APOE Genotyping Test Using Dried Blood Spots, Plasma, and Urine
Oct 26, 2026 · globenewswire.com
Niki BioSolutions Signs Agreement to Supply APOE Genotyping to Charter Research
Oct 23, 2026 · globenewswire.com
Niki BioSolutions' Rett Syndrome Biomarker Program Featured in the International Rett Syndrome Foundation's “Rett Research Tool Belt” Series
Oct 16, 2026 · globenewswire.com
Niki BioSolutions Partners with Global Alzheimer's Platform Foundation to Deliver Plasma-Based APOE Genotyping for Bio-Hermes-002
Oct 14, 2026 · globenewswire.com
Niki BioSolutions to Participate in the Lytham Partners Fall 2026 Investor Conference
Sep 25, 2026 · globenewswire.com
Data last updated: Nov 9, 2026, 04:24 AM